NIKKEI 225
40,074.69 +443.63 (+1.12%) HANG SENG
17,769.14 +50.53 (+0.29%) CRUDE OIL
83.18 -0.20 (-0.24%) GOLD FUTURES
2,333.70 -5.20 (-0.22%) DOW
39,268.35 +98.83 (+0.25%) Bitcoin GBP
49,059.04 -1,062.15 (-2.12%)
SRPT Oct 2024 180.000 call
| Previous close | 7.20 |
| Open | 7.90 |
| Bid | 5.60 |
| Ask | 6.00 |
| Strike | 180.00 |
| Expiry date | 2024-10-18 |
| Day's range | 7.20 - 7.90 |
| Contract range | N/A |
| Volume | |
| Open interest | 659 |
Business WireSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., June 28, 2024--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 28, 2024 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 23 individuals hired by Sarepta in June 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
ZacksBiotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
Alnylam Pharmaceuticals (ALNY) and Alimera Sciences, Inc. (ALIM) are in the spotlight following study and merger updates, respectively.
GuruFocus.comInsider Sale: EVP, General Counsel Ryan Brown Sells 38,957 Shares of Sarepta Therapeutics Inc (SRPT)
Ryan Brown, EVP, General Counsel of Sarepta Therapeutics Inc (NASDAQ:SRPT), sold 38,957 shares of the company on June 25, 2024.
